Targeted Protein Degradation: Clinical Advances in the Field of Oncology

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Dec 11

PMID 36499765

Authors

Abdelrahman K A A Salama

Marija V Trkulja

Emilio Casanova

Iris Z Uras

Affiliations

Soon will be listed here.

Abstract

The field of targeted protein degradation (TPD) is a rapidly developing therapeutic modality with the promise to tame disease-relevant proteins in ways that are difficult or impossible to tackle with other strategies. While we move into the third decade of TPD, multiple degrader drugs have entered the stage of the clinic and many more are expected to follow. In this review, we provide an update on the most recent advances in the field of targeted degradation with insights into possible clinical implications for cancer prevention and treatment.

Citing Articles

Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy.

Mihaylova R, Momekova D, Elincheva V, Momekov G Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770542 PMC: 11677665. DOI: 10.3390/ph17121701.

Inhibitors to degraders: Changing paradigm in drug discovery.

Haridas V, Dutta S, Munjal A, Singh S iScience. 2024; 27(5):109574.

PMID: 38646175 PMC: 11031827. DOI: 10.1016/j.isci.2024.109574.

Revolutionizing Drug Targeting Strategies: Integrating Artificial Intelligence and Structure-Based Methods in PROTAC Development.

Danishuddin , Jamal M, Song K, Lee K, Kim J, Park Y Pharmaceuticals (Basel). 2023; 16(12).

PMID: 38139776 PMC: 10747325. DOI: 10.3390/ph16121649.

Transcription factors in fibroblast plasticity and CAF heterogeneity.

Melchionna R, Trono P, Di Carlo A, Di Modugno F, Nistico P J Exp Clin Cancer Res. 2023; 42(1):347.

PMID: 38124183 PMC: 10731891. DOI: 10.1186/s13046-023-02934-4.

Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy.

Moon Y, Jeon S, Shim M, Kim K Pharmaceutics. 2023; 15(2).

PMID: 36839734 PMC: 9965039. DOI: 10.3390/pharmaceutics15020411.

References

He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S . DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. J Hematol Oncol. 2020; 13(1):95. PMC: 7364785. DOI: 10.1186/s13045-020-00928-9. View

Li X, Pu W, Zheng Q, Ai M, Chen S, Peng Y . Proteolysis-targeting chimeras (PROTACs) in cancer therapy. Mol Cancer. 2022; 21(1):99. PMC: 8996410. DOI: 10.1186/s12943-021-01434-3. View

Kounde C, Shchepinova M, Saunders C, Muelbaier M, Rackham M, Harling J . A caged E3 ligase ligand for PROTAC-mediated protein degradation with light. Chem Commun (Camb). 2020; 56(41):5532-5535. DOI: 10.1039/d0cc00523a. View

Dragovich P, Adhikari P, Blake R, Blaquiere N, Chen J, Cheng Y . Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα). Bioorg Med Chem Lett. 2020; 30(4):126907. DOI: 10.1016/j.bmcl.2019.126907. View

Costales M, Aikawa H, Li Y, Childs-Disney J, Abegg D, Hoch D . Small-molecule targeted recruitment of a nuclease to cleave an oncogenic RNA in a mouse model of metastatic cancer. Proc Natl Acad Sci U S A. 2020; 117(5):2406-2411. PMC: 7007575. DOI: 10.1073/pnas.1914286117. View

Yang X, Yin H, Kim R, Fleming J, Xie H . Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective. Target Oncol. 2020; 16(1):1-12. DOI: 10.1007/s11523-020-00782-2. View

Bond M, Crews C . Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation. RSC Chem Biol. 2021; 2(3):725-742. PMC: 8190915. DOI: 10.1039/d1cb00011j. View

Zhang H, Han Y, Yang Y, Lin F, Li K, Kong L . Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation. J Am Chem Soc. 2021; 143(40):16377-16382. DOI: 10.1021/jacs.1c08521. View

Patil K, Chin D, Seah H, Shi Q, Lim K, Phan A . G4-PROTAC: targeted degradation of a G-quadruplex binding protein. Chem Commun (Camb). 2021; 57(95):12816-12819. DOI: 10.1039/d1cc05025g. View

10.

Zhang J, Chen P, Zhu P, Zheng P, Wang T, Wang L . Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative. Bioorg Chem. 2020; 99:103817. DOI: 10.1016/j.bioorg.2020.103817. View

11.

Nabet B, Ferguson F, Seong B, Kuljanin M, Leggett A, Mohardt M . Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules. Nat Commun. 2020; 11(1):4687. PMC: 7501296. DOI: 10.1038/s41467-020-18377-w. View

12.

Gosavi P, Ngan K, Yeo M, Su C, Li J, Lue N . Profiling the Landscape of Drug Resistance Mutations in Neosubstrates to Molecular Glue Degraders. ACS Cent Sci. 2022; 8(4):417-429. PMC: 9052798. DOI: 10.1021/acscentsci.1c01603. View

13.

Cyrus K, Wehenkel M, Choi E, Swanson H, Kim K . Two-headed PROTAC: an effective new tool for targeted protein degradation. Chembiochem. 2010; 11(11):1531-4. PMC: 3852688. DOI: 10.1002/cbic.201000222. View

14.

Pfaff P, Samarasinghe K, Crews C, Carreira E . Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs. ACS Cent Sci. 2019; 5(10):1682-1690. PMC: 6813558. DOI: 10.1021/acscentsci.9b00713. View

15.

Miao Y, Gao Q, Mao M, Zhang C, Yang L, Yang Y . Bispecific Aptamer Chimeras Enable Targeted Protein Degradation on Cell Membranes. Angew Chem Int Ed Engl. 2021; 60(20):11267-11271. DOI: 10.1002/anie.202102170. View

16.

Adkins S . CAR T-Cell Therapy: Adverse Events and Management. J Adv Pract Oncol. 2021; 10(Suppl 3):21-28. PMC: 7521123. DOI: 10.6004/jadpro.2019.10.4.11. View

17.

Budde L, Berger C, Lin Y, Wang J, Lin X, Frayo S . Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS One. 2013; 8(12):e82742. PMC: 3866194. DOI: 10.1371/journal.pone.0082742. View

18.

Ng C, Banik S . Taming transcription factors with TRAFTACs. Cell Chem Biol. 2021; 28(5):588-590. DOI: 10.1016/j.chembiol.2021.04.016. View

19.

Steinebach C, Kehm H, Lindner S, Vu L, Kopff S, Lopez Marmol A . PROTAC-mediated crosstalk between E3 ligases. Chem Commun (Camb). 2019; 55(12):1821-1824. DOI: 10.1039/c8cc09541h. View

20.

Dragovich P, Pillow T, Blake R, Sadowsky J, Adaligil E, Adhikari P . Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties. J Med Chem. 2021; 64(5):2534-2575. DOI: 10.1021/acs.jmedchem.0c01845. View